Well I have a solution for that @RaceOncology is probably way ahead of me...
This is all based on the best patient outcome and not profit and margins.
Lets assume Bisantrene is bought out before FTO readouts... Race SHs agree to sell Bisantrene for Pillars 2 & 3 (AML and Breast Cancer) RACe put a clause into the sale agreement that acquiring big pharma must continue the FTO trials and must engage the Race team to complete. Failure to complete the trials allows RACe team to complete trials and sell the Bisantrene for FTO treatment. The first right of refusal goes to the big pharma that bought Bisantene for Pillars 2 & 3. ...and maybe one step further a clause for obesity as well.
Now, the above maybe somewhat simplistic... However, IMO that fact these clause are in the draft contract makes the acquiring Big Pharma stand up and listen and consider the total value of Bisantrene. I for one would make those clauses to stick and Big Pharma can pay up or not be exclusive on Bisantrene.
When it all said and done I would happy take a lower payout to ensure Bisantrene gets to market in all its forms and assists as many cancer sufferers as possible. Time to make Big Pharma agree the patient comes before profit...
RAC Price at posting:
$4.00 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)